Mirabegron
Brand name: Myrbetriq
Rank #16 of 500 drugs by total cost
$927.5M
Total Cost
1,407,073
Total Claims
$927.5M
Total Cost
31,017
Prescribers
$659
Cost per Claim
218,887
Beneficiaries
2,130,162
30-Day Fills
$30K
Avg Cost/Provider
45
Avg Claims/Provider
About Mirabegron
Mirabegron (sold as Myrbetriq) was prescribed 1,407,073 times by 31,017 Medicare Part D providers in 2023, costing the program $927.5M. At $659 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 13 | Bictegrav/Emtricit/Tenofov Ala (Biktarvy) | $1.29B | 310,738 |
| 14 | Etanercept (Enbrel Sureclick) | $1.12B | 145,737 |
| 15 | Enzalutamide (Xtandi) | $985.0M | 72,710 |
| 16 | Mirabegron (Myrbetriq) | $927.5M | 1,407,073 |
| 17 | Tirzepatide (Mounjaro) | $877.9M | 680,457 |
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
| 19 | Ustekinumab (Stelara) | $852.3M | 31,974 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology